LifeSci Startup

Big news from Amplitude Vascular Systems - The medical device company has secured $36M in Series B funding to advance its innovative PULSE IVL™ platform for treating severely calcified arterial disease. The funding will support the U.S. peripheral commercial launch and pivotal IDE trials for coronary and carotid applications. As intravascular lithotripsy (IVL) continues to gain traction, AVS is accelerating its path toward commercial approval. https://lnkd.in/eYZHM5ZY #lifescience #biotech #healthcare #funding

Biotech IPO momentum continues into January as Aardvark Therapeutics and Ascentage Pharma make moves. Aardvark, a clinical-stage metabolic company, plans to go public, showcasing its lead candidate, ARD-101. This TAS2R pan-agonist targets gut-brain signaling to suppress appetite by releasing hormones like GLP-1 and cholecystokinin. Early results suggest ARD-101 may enhance appetite control alone or alongside blockbuster drugs from Novo Nordisk and Eli Lilly. Meanwhile, Ascentage Pharma lands on #Nasdaq with a $126.4M offering. More: https://lnkd.in/gjsuyKhQ #lifescience #healthcare #obesity #IPO

Scorpius BioManufacturing, Inc. has partnered with KaloCyte, Inc. to optimize manufacturing for ErythroMer™, a groundbreaking artificial red blood cell designed to address life-threatening blood loss when stored blood is unavailable or in short supply. The collaboration aims to enhance production efficiency and explores opportunities for commercial-scale manufacturing. This is a major step toward advancing innovative solutions for critical #healthcare challenges! Learn more: https://lnkd.in/gaJz-aym #lifescience #biotech #collaboration

Big news in the fight against neuromuscular diseases - The #FDA has granted Fast Track designation to Dyne Therapeutics DYNE-101, a potential treatment for myotonic dystrophy type 1 (DM1). The therapy is being evaluated in the Phase 1/2 ACHIEVE global clinical trial. https://lnkd.in/gcXY8CrK #lifescience #biotech #healthcare

Exciting news from BioSkryb Genomics - The Durham-based innovator in single-cell and ultra-low input multiomics has launched ResolveSEQ MRD, a groundbreaking service for better classification and characterization of MRD cells in hematologic malignancies. This new offering integrates seamlessly with flow cytometry (FC) protocols to deliver unmatched single-cell genome and transcriptome insights—paving the way for advancements in precision oncology. More: https://lnkd.in/g-vf7pBz #lifescience #biotech #healthcare #oncology #innovation

AbbVie Acquires Nimble Therapeutics in $200M Immune Drug Deal This deal includes Nimble’s preclinical pipeline of oral peptide drugs targeting immune diseases like psoriasis and inflammatory bowel disease (IBD). The highlight is an oral IL-23 inhibitor, aiming to complement AbbVie’s Skyrizi injection. Nimble’s drug discovery platform for peptide-based therapies will also bolster AbbVie’s R&D capabilities. More: https://lnkd.in/gV5BPyKQ #lifescience #biotech #healthcare

Dewpoint Therapeutics and ConcertAI have launched the first phase of their Translational Oncology partnership, focused on advancing Dewpoint's drug candidate, DPTX3186. DPTX3186 targets the 'undruggable' beta-catenin oncogenic function, addressing Wnt-driven tumors like colorectal, breast, lung, and gastric cancers. This partnership combines Dewpoint’s AI/ML-powered discovery platform with ConcertAI’s clinico-genomic data and CARAai™ platform to optimize patient stratification. Learn more: https://lnkd.in/gXqBrf5G #Biotech #Oncology #AI #Partnership #Innovation #Healthcare #lifescience

Alamar Biosciences, Inc., a leader in precision proteomics, has announced the installation of its ARGO™ HT System—an advanced proteomics platform—at the prestigious Hong Kong Center for Neurodegenerative Diseases (HKCeND). This milestone marks the company’s growing presence in the Asia Pacific region and its mission to empower researchers with tools for the earliest detection of disease and groundbreaking biomarker discovery. Dr. Yuling Luo, Founder, Chairman, and CEO of Alamar Biosciences, shared: "Expanding our ARGO HT platform to APAC marks a significant step in bringing transformative proteomics solutions to researchers worldwide." 🔗 Learn more: https://lnkd.in/g7CAmeKg #lifescience #biotech #healthcare #proteomics #research

Big news in oncology! Merus N.V. announced #FDA approval for BIZENGRI, the first and only treatment for advanced pancreatic adenocarcinoma or non-small cell lung cancer with neuregulin 1 gene fusion. This marks a major milestone for patients with progressive, unresectable, or metastatic disease after prior systemic therapy. Learn more: https://lnkd.in/eSJk7uPS #Oncology #FDAApproval #CancerResearch #Biotech #Healthcare #Lifescience

Parse Biosciences, a leader in accessible and scalable single-cell sequencing solutions, welcomes OMAPiX as the newest member of its Certified Service Provider (CSP) Program. With this partnership, OMAPiX joins a distinguished network of service labs offering Parse’s scalable single cell technology to researchers worldwide. More: https://lnkd.in/g83ej575 #lifescience #biotech #healthcare